Benztropine mesylate

Research use only, not for human use.

Benzatropine is an anticholinergic drug used in patients to reduce the side effects of antipsychotic treatment.

Benzatropine is an anticholinergic drug used in patients to reduce the side effects of antipsychotic treatment. Benzatropine is also a second-line drug for the treatment of Parkinson's disease. It improves tremor, but not rigidity and bradykinesia. (In Vitro):Benztropine mesylate (0.1-10 μM; 72 hours) treatment inhibits the cell growth of MDA-MB-231 cells with an IC50 of ~5 μM. In MDA-MB-231 cells and 4T1-luc2 cells, Benztropine mesylate reduces the size as well as the number of mammospheres significantly in a dose-dependent manne.Benztropine mesylate inhibits functions of cancer stem cells (CSCs) via the acetylcholine receptors, dopamine transporters/receptors, and/or histamine receptors.Benztropine mesylate induces the differentiation of oligodendrocytes through M1 and M3 muscarinic receptors and enhanced re-myelination.(In Vivo):Benztropine mesylate (1.5 mg/kg; daily; for 3 weeks; Balb/c mice) treatment significantly reduces both tumor size and tumor weight in a 4T1 mouse model.

Cell Viability Assay Cell Line:MDA-MB-231 cells Concentration:0.1 μM, 0.625 μM, 1.25 μM, 2.5 μM, 5 μM, 10 μM Incubation Time:72 hours Result:Inhibited the cell growth of MDA-MB-231 cells with an IC50 of ~5 μM.Cell Proliferation Assay Cell Line:MDA-MB-231 cells Concentration:0, 1, 2, 5 μM Incubation Time:4-6 days Result:Suppressed mammosphere formation and self-renewal capacities of BCSCs in a dose-dependent manner in vitro.

——

NSC 169913

GPCR/G Protein

Dopamine Receptor

DAT

Neurological Disease

——

132-17-2

403.53

C21H25NO·CH4SO3

>98% (HPLC)

Ethanol: 81 mg/mL (200.72 mM); Water: 81 mg/mL (200.72 mM); DMSO: 50 mg/mL (123.9 mM)

CN1[C@@H]2C[C@@H](OC(C3=CC=CC=C3)C4=CC=CC=C4)C[C@H]1CC2.OS(C)(=O)=O

(1R,3r,5S)-3-(benzhydryloxy)-8-methyl-8-azabicyclo[3.2.1]octane methanesulfonate

(-20℃)

With Ice Pack

≥ 2 years